USPTO Patent Grant: RAS Oncoprotein Inhibitors

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12582660B2 to the University of Louisville Research Foundation, Inc. for inhibitors of the RAS oncoprotein, methods of making, and methods of use thereof. The patent covers compounds useful in treating diseases associated with activating mutations in RAS, particularly cancer.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12582660B2, covering compounds for treating diseases associated with RAS oncoprotein activity, including cancer. The patent, assigned to the University of Louisville Research Foundation, Inc., details specific compounds of Formula (I) and their therapeutic applications.

This patent grant signifies a new intellectual property right for the assignee. While not a regulatory mandate for other entities, it establishes exclusive rights for the patent holder in the US for the claimed inventions. Companies involved in oncology drug development, particularly those targeting RAS pathways, should be aware of this granted patent to avoid potential infringement and to understand the competitive landscape.

Source document (simplified)

← USPTO Patent Grants

Inhibitors of the RAS oncoprotein, methods of making and methods of use thereof

Grant US12582660B2 Kind: B2 Mar 24, 2026

Assignee

University of Louisville Research Foundation, Inc.

Inventors

Geoffrey J. Clark, John O. Trent, Joseph A. Burlison

Abstract

A compound for use in treating a disease associated with activating mutations in RAS, or for use in treating a disease treatable by a reduction in RAS activity, is selected from a compound of Formula (I), salts and esters thereof. The compounds are particularly useful in treating cancer.